Salesforce Friends ...
Health Care: Drugs
Columbia Laboratories Inc. (CBRX: NASDAQ)
$0.68 0.00 | 0.00%
06/04/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 43.06M | 45.68M | 32.20M | 36.34M |
| Cost of Sales | 11.52M | 6.79M | 5.61M | 7.91M |
| Gross Operating Profit | 31.54M | 38.89M | 26.59M | 28.43M |
| Selling, General, and Administrative Expenses | 8.20M | 24.38M | 22.54M | 21.41M |
| Research & Development | 2.78M | 8.58M | 8.58M | 6.21M |
| Operating Income before D & A (EBITDA) | 20.56M | 5.93M | -4.54M | 812.20K |
| Depreciation & Amortization | 166.99K | 4.75M | 8.63M | 8.07M |
| Interest Income | 107.26K | 28.84K | 33.83K | 299.80K |
| Other Income - Net | -2.46M | -18.67M | -243.72K | -100.52K |
| Special Income / Charges | 2.53M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 20.58M | -17.47M | -13.37M | -7.06M |
| Interest Expense | 12.11K | 4.84M | 8.85M | 7.88M |
| Pre-Tax Income | 20.57M | -22.31M | -22.22M | -14.94M |
| Income Taxes | 39.28K | -475.42K | -355.03K | -863.77K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 20.53M | -21.83M | -21.87M | -14.08M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 20.53M | -21.83M | -21.87M | -14.08M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 20.53M | -21.83M | -21.87M | -14.08M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
17.99M | -21.83M | -21.87M | -14.08M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 20.53M | -21.83M | -21.87M | -14.13M |
| Basic EPS from Continuing Ops. | 0.24 | -0.30 | -0.39 | -0.27 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.24 | -0.30 | -0.39 | -0.27 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.24 | -0.30 | -0.39 | -0.27 |
| Basic Normalized Net Income/Share | 0.21 | -0.30 | -0.39 | -0.27 |
| EPS fr Continuing Ops. | 0.22 | -0.30 | -0.39 | -0.27 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.22 | -0.30 | -0.39 | -0.27 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.22 | -0.30 | -0.39 | -0.27 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.19 | -0.30 | -0.39 | -0.27 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CBRX
- Portfolio NameUser Type
- UserMy Portfolio
- Contributor11 Stocks Under $4 With Upside
- Usermincronn Portfolio 1
- Usercscob Portfolio 1
- Userpharmer
- UserSUPRATRADE 2307070204
- UserSUPRATRADE VIRTUAL SKY
- Userstock fund
- UserBob700 Portfolio 1
- UserDunroamins
Latest CBRX Headlines from TheStreet
- A Classic Biotech Long Shot 04.05.12 | 09:04 am
- Columbia Stock Gaps Down On Today's Open (CBRX) 02.27.12 | 08:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Columbia Stock Soars (CBRX) 01.24.12 | 12:01 pm
- Columbia Stock Gaps Down On Today's Open (CBRX) 01.23.12 | 08:01 am
- Columbia Stock Gaps Up On Today's Open (CBRX) 01.18.12 | 08:01 am
- Columbia Laboratories Inc. Stock Upgraded (CBRX) 08.10.11 | 07:08 am
- 11 Stocks Under $4 With Upside: Analysts 05.11.11 | 12:05 pm
- Biotech Calendar: Key Dates for May 05.02.11 | 09:05 am
- Columbia Stock Falls On Unusually High Volume (CBRX) 04.06.11 | 02:04 pm
Press Releases for CBRX
- Columbia Laboratories Reports First Quarter 2012 Financial Results - Business Wire 05.04.12 | 06:05 am
- Columbia Laboratories Hires Cowen And Company To Assist In Evaluating Potential Strategic Transactions - Business Wire 03.13.12 | 06:03 am
- Columbia Laboratories Reports Fourth Quarter And Year-End 2011 Financial Results - Business Wire 03.08.12 | 06:03 am
- Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter - Business Wire 03.06.12 | 04:03 pm
- Columbia Laboratories Announces 42% Workforce Reduction - Business Wire 03.01.12 | 04:03 pm
- Columbia Laboratories To Discuss Fourth Quarter And Year-End 2011 Financial Results On March 8, 2012, Conference Call - Business Wire 03.01.12 | 06:03 am
- Columbia Laboratories Will Present March 5th At Cowen And Company Health Care Conference - Business Wire 02.29.12 | 06:02 am
- Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories Inc. - PR Newswire 02.09.12 | 11:02 am
- The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In Columbia Laboratories Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2012 To Seek A Lead Plaintiff Position - Business Wire 02.02.12 | 02:02 pm
- Bronstein, Gewirtz & Grossman, LLC Investigates Columbia Laboratories, Inc. - Business Wire 01.23.12 | 10:01 am
Partner Headlines for CBRX
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- Market Losers - Benzinga 01.23.12 | 01:01 pm
- Columbia Labs Plummet after Recommendation Denial by FDA - Benzinga 01.23.12 | 09:01 am
- FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length - Benzinga 01.20.12 | 04:01 pm
- Watson Pharma and Columbia Labs Plunge on Proposed FDA Review - Benzinga 01.17.12 | 01:01 pm
- Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA - Benzinga 11.10.11 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 09.16.11 | 09:09 am
- Watson to Market Antares' OAB Drug - Analyst Blog - Zacks 07.12.11 | 10:07 am
- Upcoming PDUFA Dates for Sub-$5 Stocks - Seeking Alpha 07.05.11 | 09:07 am
